246 related articles for article (PubMed ID: 26190800)
1. Methotrexate influx via folate transporters into alveolar epithelial cell line A549.
Kawami M; Miyamoto M; Yumoto R; Takano M
Drug Metab Pharmacokinet; 2015 Aug; 30(4):276-81. PubMed ID: 26190800
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells.
Kühnel JM; Chiao JH; Sirotnak FM
J Cell Physiol; 2000 Sep; 184(3):364-72. PubMed ID: 10911368
[TBL] [Abstract][Full Text] [Related]
3. Reduced folate carrier-mediated methotrexate transport in human distal lung epithelial NCl-H441 cells.
Kawami M; Honda N; Miyamoto M; Yumoto R; Takano M
J Pharm Pharmacol; 2019 Feb; 71(2):167-175. PubMed ID: 30324648
[TBL] [Abstract][Full Text] [Related]
4. The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells.
Zhao R; Hanscom M; Goldman ID
Biochim Biophys Acta; 2005 Aug; 1715(1):57-64. PubMed ID: 16109384
[TBL] [Abstract][Full Text] [Related]
5. Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function.
Sierra EE; Goldman ID
Biochem Pharmacol; 1998 May; 55(9):1505-12. PubMed ID: 10076544
[TBL] [Abstract][Full Text] [Related]
6. Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.
Biswal BK; Verma RS
J Biochem; 2009 Nov; 146(5):693-703. PubMed ID: 19692428
[TBL] [Abstract][Full Text] [Related]
7. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
[TBL] [Abstract][Full Text] [Related]
8. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
Zhao R; Gao F; Hanscom M; Goldman ID
Clin Cancer Res; 2004 Jan; 10(2):718-27. PubMed ID: 14760095
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter.
Nakai Y; Inoue K; Abe N; Hatakeyama M; Ohta KY; Otagiri M; Hayashi Y; Yuasa H
J Pharmacol Exp Ther; 2007 Aug; 322(2):469-76. PubMed ID: 17475902
[TBL] [Abstract][Full Text] [Related]
10. Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats.
Yokooji T; Mori N; Murakami T
J Pharm Pharmacol; 2009 Jul; 61(7):911-8. PubMed ID: 19589233
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
12. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.
Hou Z; Matherly LH
Curr Top Membr; 2014; 73():175-204. PubMed ID: 24745983
[TBL] [Abstract][Full Text] [Related]
13. Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1.
Unal ES; Zhao R; Goldman ID
Am J Physiol Cell Physiol; 2009 Jul; 297(1):C66-74. PubMed ID: 19403800
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective transport of amethopterin enantiomers by the proton-coupled folate transporter.
Narawa T; Itoh T
Drug Metab Pharmacokinet; 2010; 25(3):283-9. PubMed ID: 20610887
[TBL] [Abstract][Full Text] [Related]
15. Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells.
Assaraf YG; Babani S; Goldman ID
J Biol Chem; 1998 Apr; 273(14):8106-11. PubMed ID: 9525913
[TBL] [Abstract][Full Text] [Related]
16. Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function.
Wang Y; Rajgopal A; Goldman ID; Zhao R
Am J Physiol Cell Physiol; 2005 Jan; 288(1):C65-71. PubMed ID: 15385270
[TBL] [Abstract][Full Text] [Related]
17. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.
Matherly LH; Wilson MR; Hou Z
Drug Metab Dispos; 2014 Apr; 42(4):632-49. PubMed ID: 24396145
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells.
Spinella MJ; Brigle KE; Sierra EE; Goldman ID
J Biol Chem; 1995 Apr; 270(14):7842-9. PubMed ID: 7713875
[TBL] [Abstract][Full Text] [Related]
19. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities.
Rajgopal A; Sierra EE; Zhao R; Goldman ID
Am J Physiol Cell Physiol; 2001 Nov; 281(5):C1579-86. PubMed ID: 11600421
[TBL] [Abstract][Full Text] [Related]
20. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
